The remarkable progress in the understanding the biology of ErbB signaling in cancer has led to the discovery of several targeted agents against ErbB members, including small molecule tyrosine kinase inhibitors (TKIs) and monoclonal antibodies (MAbs). This evidence concerns the gene EGFR and cancer.